The Spanish Pharmaceutical Sector Falls 5.8% in the Third Quarter

Spanish pharmaceutical companies listed on the continuous market close the third quarter of 2021 in the red. The aggregate capitalization of Grifols, Almirall, Rovi, Faes Farma, Pharma Mar, and Reig Jofre fell by 5.8% between June and September.

The performance of the pharmaceutical sector in the third quarter was worse than that of the Ibex35, the Spanish benchmark index, which fell by 0.3% in the same period. The six listed pharmaceutical companies closed the third quarter with a stock market value of $20 billion (€17.3 billion), compared to $21.3 billion (€18.4 billion) at the end of the previous quarter. This decline occurred in all companies except for Faes Farma, whose shares rose by a slight 0.6%.

Read more on the subject and find other important financial news with our companion app Born2Invest.

The six listed pharmaceutical companies closed the third quarter with a stock market value of $20 billion (€17.3 billion)

The biggest fall was for Reig Jofre. The pharmaceutical company’s shares corrected by 8.45% in the period, to $5.2 (€4.5) per share. The company closed the first half of 2021 with a profit of $4 million (€3.5 million), which translates into a 7.7% drop compared to the same period in 2020, according to the latest available data.

The second-largest decline was recorded by Grifols. The Catalan pharmaceutical company’s shares fell by 7.5% to $24.4 (€21.08). Nevertheless, Grifols continues to be the pharmaceutical company with the largest capitalization, with more than $10.3 billion (€8.9 billion).

A few days ago, the company specialized in the production of plasma derivatives began the process for the issue of senior unsecured bonds for $2.3 billion (€2 billion) with a maturity date of 2028 to finance the purchase of the German company Biotest. This acquisition has increased its indebtedness more than five times and has caused S&P Ratings to downgrade its credit rating to BB- from the previous BB.

Almirall closed the third quarter in the stock market with a 6.7% drop, to $15.9 (€13.7) per share

Grifols is followed by Almirall. The pharmaceutical company, owned by the Gallardo family, which last May increased its share capital by more than $347,000 (€300,000), closed the third quarter on the stock exchange with a 6.7% drop, to $15.9 (€13.7)per share.

The Catalan pharmaceutical company recorded a loss of $49.6 million (€42.8 million) in the first half of the year, compared to a profit of $49 million (€42.4 million) in the same period of 2020.

Rovi and Pharma Mar also fell on the stock market. The shares of the former fell to $65.4 (€56.5) per share at the end of the third quarter, compared to $67.6 (€58.4) in the second quarter. The shares of the Galician company stood at $86 (€74.4) per share, down 1.8% compared to the previous quarter.

__

(Featured image by AbsolutVision via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.